Cargando…
Prognostic and clinicopathological value of MUC1 expression in colorectal cancer: A meta-analysis
BACKGROUND: Accumulating evidence supports the overexpression of mucin 1 (MUC1) in colorectal cancer (CRC), but the value of elevated MUC1 expression remains controversial. Here, we evaluated the prognostic and clinicopathological value of MUC1 expression in CRC. MATERIALS AND METHODS: The Web of Sc...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831235/ https://www.ncbi.nlm.nih.gov/pubmed/30817589 http://dx.doi.org/10.1097/MD.0000000000014659 |
_version_ | 1783465922021818368 |
---|---|
author | Li, Chao Liu, Tao Yin, Libin Zuo, Didi Lin, Yuyang Wang, Lei |
author_facet | Li, Chao Liu, Tao Yin, Libin Zuo, Didi Lin, Yuyang Wang, Lei |
author_sort | Li, Chao |
collection | PubMed |
description | BACKGROUND: Accumulating evidence supports the overexpression of mucin 1 (MUC1) in colorectal cancer (CRC), but the value of elevated MUC1 expression remains controversial. Here, we evaluated the prognostic and clinicopathological value of MUC1 expression in CRC. MATERIALS AND METHODS: The Web of Science, PubMed, Embase, Cochrane Library, and Wanfang databases, as well as the China Biology Medicine disc (CBMdisc) and China National Knowledge Infrastructure (CNKI) were searched for studies on MUC1 expression and prognosis of CRC through July 20, 2018. The pooled relative risks (RRs) and hazard ratios (HRs) with 95% confidence intervals (95% CIs) were calculated to evaluate the prognostic and clinicopathological value of MUC1 expression in CRC. The Revman version 5.3 package and STATA, version 12 were employed for pooled analysis and analysis of publication bias. RESULTS: This meta-analysis included 16 published studies. The combined analysis showed that CRC patients with high MUC1 expression had a worse clinical outcome in overall survival (OS) (HR = 1.51, 95% CI = 1.30–1.75, P <.00001). In addition, high MUC1 expression was associated with higher TNM stage (RR = 1.44, 95% CI = 1.17–1.77, P = .0007), greater depth of invasion (RR = 1.30, 95% CI = 1.10–1.53, P = .002), and lymph node metastasis (RR = 1.47, 95% CI = 1.20–1.80, P = .0002) of CRC. However, the elevated MUC1 expression was not related to disease-free survival/recurrence-free survival (DFS/RFS) (HR = 1.51, 95% CI = 0.78–2.89, P = .22), histological grade (RR = 1.15, 95% CI = 0.96–1.38, P = .12), gender (RR = 0.95; 95% CI = 0.83–1.08, P = .44), tumor size (RR = 1.11, 95% CI = 0.85–1.44, P = .44), tumor site (RR = 1.01, 95% CI = 0.88–1.16, P = .84), or mucinous component (RR = 0.83, 95% CI = 0.60–1.14, P = .24) in CRC. CONCLUSION: Our findings indicated that high MUC1 expression represents a marker of poor prognosis in CRC. Meanwhile, elevated MUC1 expression was associated with advanced TNM stage, greater depth of invasion, and lymph node metastasis. |
format | Online Article Text |
id | pubmed-6831235 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-68312352019-11-19 Prognostic and clinicopathological value of MUC1 expression in colorectal cancer: A meta-analysis Li, Chao Liu, Tao Yin, Libin Zuo, Didi Lin, Yuyang Wang, Lei Medicine (Baltimore) 4500 BACKGROUND: Accumulating evidence supports the overexpression of mucin 1 (MUC1) in colorectal cancer (CRC), but the value of elevated MUC1 expression remains controversial. Here, we evaluated the prognostic and clinicopathological value of MUC1 expression in CRC. MATERIALS AND METHODS: The Web of Science, PubMed, Embase, Cochrane Library, and Wanfang databases, as well as the China Biology Medicine disc (CBMdisc) and China National Knowledge Infrastructure (CNKI) were searched for studies on MUC1 expression and prognosis of CRC through July 20, 2018. The pooled relative risks (RRs) and hazard ratios (HRs) with 95% confidence intervals (95% CIs) were calculated to evaluate the prognostic and clinicopathological value of MUC1 expression in CRC. The Revman version 5.3 package and STATA, version 12 were employed for pooled analysis and analysis of publication bias. RESULTS: This meta-analysis included 16 published studies. The combined analysis showed that CRC patients with high MUC1 expression had a worse clinical outcome in overall survival (OS) (HR = 1.51, 95% CI = 1.30–1.75, P <.00001). In addition, high MUC1 expression was associated with higher TNM stage (RR = 1.44, 95% CI = 1.17–1.77, P = .0007), greater depth of invasion (RR = 1.30, 95% CI = 1.10–1.53, P = .002), and lymph node metastasis (RR = 1.47, 95% CI = 1.20–1.80, P = .0002) of CRC. However, the elevated MUC1 expression was not related to disease-free survival/recurrence-free survival (DFS/RFS) (HR = 1.51, 95% CI = 0.78–2.89, P = .22), histological grade (RR = 1.15, 95% CI = 0.96–1.38, P = .12), gender (RR = 0.95; 95% CI = 0.83–1.08, P = .44), tumor size (RR = 1.11, 95% CI = 0.85–1.44, P = .44), tumor site (RR = 1.01, 95% CI = 0.88–1.16, P = .84), or mucinous component (RR = 0.83, 95% CI = 0.60–1.14, P = .24) in CRC. CONCLUSION: Our findings indicated that high MUC1 expression represents a marker of poor prognosis in CRC. Meanwhile, elevated MUC1 expression was associated with advanced TNM stage, greater depth of invasion, and lymph node metastasis. Wolters Kluwer Health 2019-03-01 /pmc/articles/PMC6831235/ /pubmed/30817589 http://dx.doi.org/10.1097/MD.0000000000014659 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 |
spellingShingle | 4500 Li, Chao Liu, Tao Yin, Libin Zuo, Didi Lin, Yuyang Wang, Lei Prognostic and clinicopathological value of MUC1 expression in colorectal cancer: A meta-analysis |
title | Prognostic and clinicopathological value of MUC1 expression in colorectal cancer: A meta-analysis |
title_full | Prognostic and clinicopathological value of MUC1 expression in colorectal cancer: A meta-analysis |
title_fullStr | Prognostic and clinicopathological value of MUC1 expression in colorectal cancer: A meta-analysis |
title_full_unstemmed | Prognostic and clinicopathological value of MUC1 expression in colorectal cancer: A meta-analysis |
title_short | Prognostic and clinicopathological value of MUC1 expression in colorectal cancer: A meta-analysis |
title_sort | prognostic and clinicopathological value of muc1 expression in colorectal cancer: a meta-analysis |
topic | 4500 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831235/ https://www.ncbi.nlm.nih.gov/pubmed/30817589 http://dx.doi.org/10.1097/MD.0000000000014659 |
work_keys_str_mv | AT lichao prognosticandclinicopathologicalvalueofmuc1expressionincolorectalcancerametaanalysis AT liutao prognosticandclinicopathologicalvalueofmuc1expressionincolorectalcancerametaanalysis AT yinlibin prognosticandclinicopathologicalvalueofmuc1expressionincolorectalcancerametaanalysis AT zuodidi prognosticandclinicopathologicalvalueofmuc1expressionincolorectalcancerametaanalysis AT linyuyang prognosticandclinicopathologicalvalueofmuc1expressionincolorectalcancerametaanalysis AT wanglei prognosticandclinicopathologicalvalueofmuc1expressionincolorectalcancerametaanalysis |